What is a Poor Metabolizer?

Poor metabolizer status is defined by carrying two non-functional or reduced-function alleles of a CYP gene. For CYP2D6, the most clinically significant poor metabolizer genotype is *4/*4 (homozygous for rs3892097 A alleles), which occurs in approximately 5-10% of Europeans. These individuals produce no functional CYP2D6 enzyme. When prescribed codeine, they cannot convert it to its active metabolite morphine, resulting in no pain relief. Conversely, when prescribed drugs that are inactivated by CYP2D6 (like tamoxifen's activation to endoxifen), the consequences differ. For CYP2C19, the *2/*2 genotype (rs4244285 AA) creates poor metabolizer status, affecting clopidogrel activation — these patients have a 1.5 to 3-fold increased risk of cardiovascular events when prescribed standard clopidogrel doses.

Clinical guidelines from CPIC and DPWG provide specific dosing recommendations for poor metabolizers. For a CYP2D6 PM prescribed tramadol, the recommendation is to use an alternative analgesic (not metabolized by CYP2D6) or reduce the dose by 30%. For a CYP2C19 PM prescribed clopidogrel, the recommendation is to use prasugrel or ticagrelor instead. For a CYP2C19 PM prescribed omeprazole, the dose should be reduced by 50% because poor metabolizers achieve 5-fold higher plasma levels. The FDA now includes pharmacogenomic testing recommendations or requirements on the labels of many affected drugs, and some institutions have implemented pre-emptive pharmacogenomic testing panels that genotype multiple CYP genes before any drug is prescribed.

In PepFold's pharmacogenomic pipeline, identifying poor metabolizer status helps contextualize the patient's drug response profile. When a user submits CYP-related rsIDs, the system annotates the metabolizer phenotype and factors this into the peptide design strategy. For patients who are poor metabolizers of conventional drugs, peptide therapeutic alternatives may offer particular advantage because peptides are metabolized by proteases rather than CYP enzymes, potentially bypassing the metabolic bottleneck entirely. PepFold highlights this clinical context in its analysis reports.